<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04582448</url>
  </required_header>
  <id_info>
    <org_study_id>NN1436-4572</org_study_id>
    <secondary_id>U1111-1244-4495</secondary_id>
    <secondary_id>2019-004660-21</secondary_id>
    <nct_id>NCT04582448</nct_id>
  </id_info>
  <brief_title>A Study Looking at How Insulin Icodec is Taken up in the Blood When Administered in Different Injection Sites in People With Type 2 Diabetes</brief_title>
  <official_title>A Trial Investigating the Pharmacokinetic Properties of Insulin Icodec After Administration in Different Injection Regions in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is comparing the concentration of a single dose of insulin icodec when&#xD;
      administered in the belly, upper arm and thigh on different occasions.&#xD;
&#xD;
      Participants will receive one injection of insulin icodec on three different occasions, each&#xD;
      time injected at a different site, i.e. either on our belly, upper arm or thigh.&#xD;
&#xD;
      The study will last for about 34 weeks. Participants will have 23 visits with the study&#xD;
      doctor. Informed Consent (V0) visit and screening visit (V1) will be performed on two&#xD;
      different days. The informed consent visit may be performed via telephone to minimize&#xD;
      personal contact with site staff during the coronavirus outbreak.&#xD;
&#xD;
      Women cannot take part if pregnant, breast- feeding or plan to become pregnant during the&#xD;
      study period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Actual">September 27, 2021</completion_date>
  <primary_completion_date type="Actual">September 27, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCIco,0-inf,SD, Area under the serum insulin icodec concentration-time curve after a single dose</measure>
    <time_frame>Day 1</time_frame>
    <description>From 0 hours until infinity after trial product administration (pmol*h/L)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax,Ico,SD, Maximum observed serum insulin icodec concentration after a single dose</measure>
    <time_frame>Day 1</time_frame>
    <description>From 0 hours until infinity after trial product administration (pmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax,Ico,SD, Time to maximum observed serum insulin icodec concentration after a single dose</measure>
    <time_frame>Day 1</time_frame>
    <description>From 0 hours until infinity after trial product administration (hours)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Insulin icodec treatment sequence with injection region abdomen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will be randomised to one of six treatment sequences, consisting of three single-dose administrations of insulin icodec (s.c. in the abdomen, the upper arm and the thigh) in a balanced manner on three separate treatment visits.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin icodec treatment sequence with injection region upper arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will be randomised to one of six treatment sequences, consisting of three single-dose administrations of insulin icodec (s.c. in the abdomen, the upper arm and the thigh) in a balanced manner on three separate treatment visits.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin icodec treatment sequence with injection region thigh</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will be randomised to one of six treatment sequences, consisting of three single-dose administrations of insulin icodec (s.c. in the abdomen, the upper arm and the thigh) in a balanced manner on three separate treatment visits.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin icodec</intervention_name>
    <description>A single dose of insulin icodec administered subcutaneously (s.c. - under the skin) Injection in the belly, upper arm and thigh on different occasions.</description>
    <arm_group_label>Insulin icodec treatment sequence with injection region abdomen</arm_group_label>
    <arm_group_label>Insulin icodec treatment sequence with injection region thigh</arm_group_label>
    <arm_group_label>Insulin icodec treatment sequence with injection region upper arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Aged 18-69 years (both inclusive) at the time of signing informed consent&#xD;
&#xD;
          -  Body mass index between 18.5 and 38.0 kg/m^2 (both inclusive)&#xD;
&#xD;
          -  Diagnosed with type 2 diabetes mellitus above or equal to 180 days prior to the day of&#xD;
             screening&#xD;
&#xD;
          -  HbA1c (glycated haemoglobin) below or equal to 9.0 percentage at screening&#xD;
&#xD;
          -  Current daily basal insulin treatment of 0.2-1.0 (I)U/kg/day (both inclusive) with or&#xD;
             without any of the following anti-diabetic drugs/regimens with stable doses above or&#xD;
             equal to 90 days prior to the day of screening:&#xD;
&#xD;
          -  Any metformin formulation&#xD;
&#xD;
          -  Other oral antidiabetic drugs: DPP-4 inhibitors / SGLT2 inhibitors / Oral combination&#xD;
             products (for the allowed individual oral antidiabetic drugs)&#xD;
&#xD;
          -  Oral or injectable GLP-1 (glucagon-like peptide 1) Receptor Agonists&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected hypersensitivity to trial product(s) or related products.&#xD;
&#xD;
          -  Female who is pregnant, breast-feeding or intends to become pregnant or is of&#xD;
             child-bearing potential and not using an adequate contraceptive method (adequate&#xD;
             contraceptive measures as required by local regulation or practice).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Transparency (dept. 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mainz</city>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 8, 2020</study_first_submitted>
  <study_first_submitted_qc>October 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

